In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novartis purchases SB's Famvir and Vectavir/Denavir

Executive Summary

In a deal worth $1.63bn, pharmaceutical conglomerate Novartis will acquire SmithKline Beecham's antiviral products Famvir (famciclovir) and Vectavir/Denavir (penciclovir). SB is divesting its antiviral line due to antitrust concerns in conjunction with its merger with Glaxo Wellcome.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Product Purchase

Related Companies